查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球抗体药物偶联物 (ADC) 增长机会，预测至 2028 年
市场调查报告书
商品编码
1322942

全球抗体药物偶联物 (ADC) 增长机会，预测至 2028 年

Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028
出版日期: | 出版商: Frost & Sullivan | 英文 55 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

与创新平台开发商的合作推动增长潜力

该研究服务提供了全球 ADC 市场的概况，并提供了从 2023 年到 2028 年的六年收入预测。 ADC 由多个组件结构，例如抗体、缀合化学、连接子和有效负载。市场竞争非常激烈，许多公司致力于每个结构要素，而其他公司则仅开发 ADC。超越标准抗体的靶向递送载体的开发正在提高这些药物的效力并开闢新的癌症治疗可能性。新技术旨在解决现有 ADC 技术的缺点，包括稳定性低、耐受性差、疗效低、治疗指数窄以及 ADC 製造方面的挑战。

根据 Frost & Sullivan 的分析，依赖委外研发机构(CDMO)/合同委外研发机构(CRO) 进行早期药物开发的中小企业正在创造新型抗体治疗技术。许多抗体开发商正在减少内部研发工作，并增加抗体治疗产品线的许可和收购，以加强其管道。所有主要 CDMO 都在进行新投资以支持下一代 ADC，从而使该细分市场更具竞争力。生物製药公司正在转向 ADC，以从选择性肿瘤抗原的靶点特异性中获益。 ADC 在过去两年中已获得七项批准，反映出开发人员使用稳健的方法来提高有效负载效力的成功率。

本报告中包含的其他资讯包括：

  • 市场趋势
  • 主要破坏者
  • 推动血液肿瘤和实体瘤增长的 ADC 市场投入和产品线
  • 相关人员可以利用的领域增长机会

目录

战略问题

  • 为什么成长如此困难？
  • The Strategic Imperative 8（TM）
  • ADC 行业三大战略问题的影响
  • 支撑增长管道引擎 (TM) 的增长机会

成长环境

  • 分析范围
  • ADC 市场亮点
  • 增长机会：ADC 市场
  • 增长促进因素
  • 生长阻碍因素
  • 药物偶联物的历史、进展和研究阶段
  • ADC市场趋势
  • ADC技术的演变
  • ADC 的精准肿瘤学方法
  • 生物标誌物在癌症领域的应用
  • 生命週期管理策略
  • ADC交易与投资预测
  • 着名的 ADC 合作伙伴和联盟 (2022)
  • 着名的 ADC 合作伙伴和联盟（2022 年和 2023 年）
  • 批准的 ADC 血液系统恶性肿瘤
  • 批准的 ADC 实体瘤
  • 一位着名的后期 ADC

收入预测与分析

  • 预测假设
  • 成长指数
  • 收入预测
  • 盈利预测分析：实体瘤（已推出）
  • 盈利预测分析：实体瘤（管道）
  • 盈利预测分析：血液癌症（已推出）
  • 盈利预测分析：血液癌症（后期管道）

采取行动的公司 扰乱 ADC 市场的公司

  • Tubulis 广泛的技术平台
  • LCB：共轭技术平台
  • Synaffix (Lonza)：端到端 ADC 服务
  • WuXi Biologics：ADC CRDMO
  • Mersana Therapeutics 后期 ADC 管道和平台
  • Ixuda ADC 开发的工具箱方法

充满增长机会的宇宙

  • 增长机会一：精准化疗的ADC联合疗法
  • 增长机会2：CDMO与早期平台和ADC开发商之间的战略合作伙伴关係
  • 增长机会 3：新型接头和共轭化学
  • 图表列表
  • 免责声明
简介目录
Product Code: PED8-52

Collaborations with Innovative Platform Developers will Drive Growth Potential

This research service overviews the global ADC market and provides a 6-year revenue forecast from 2023 to 2028. An ADC comprises multiple components such as the antibody, conjugation chemistry, linker, and payload. Many companies are working on each component while others only develop ADCs, which makes the market highly competitive. The development of targeted delivery vehicles over standard antibodies is improving the performance of these drugs and expanding their potential for treating new cancers. New technologies are trying to address drawbacks of existing ADC technology, such as poor stability, leading to poor tolerability, efficacy, and a narrow therapeutic index and challenging ADC manufacturing.

Frost & Sullivan's analysis shows that small and mid-sized enterprises that rely on contract development and manufacturing organizations (CDMOs)/contract research organizations (CROs) for initial drug development create novel antibody therapeutic technologies. Many antibody developers have been decreasing in-house R&D efforts and increasing in-licensing or acquiring therapeutic antibody product lines to strengthen their pipelines. All major CDMOs are stepping up with new investments to support the next generation of ADC, making the segment more competitive. Biopharmaceutical companies are focusing on ADCs to reap the benefits of target specificity for selective tumor antigens. Developers are using robust approaches to improve payloads' potency as ADCs reflect the success rate in the last two years with seven approvals.

Other information included in the report consists of the following:

  • Market trends
  • Leading disruptors
  • Marketed and pipeline ADC that will drive growth in hematological and solid tumors
  • Growth opportunities emerging from this space that stakeholders can leverage

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the ADC Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Environment

  • Scope of Analysis
  • ADC Market Highlights
  • Growth Opportunities: The ADC Market
  • Growth Drivers
  • Growth Restraints
  • Drug Conjugates' History, Progress, and Research Stages
  • ADC Market Trends
  • ADC Technology Evolution
  • Precision Oncology Approaches for ADCs
  • Biomarker Application Across the Cancer Continuum
  • Life Cycle Management Strategies
  • ADC Deals and Investment Outlook
  • Notable ADC Partnerships and Collaborations, 2022
  • Notable ADC Partnerships and Collaborations, 2022 and 2023
  • Approved ADCs: Hematological Cancer
  • Approved ADCs: Solid Tumors
  • Late-stage ADCs to Watch

Revenue Forecast and Analysis

  • Forecast Assumptions
  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast Analysis: Solid Tumors (Launched)
  • Revenue Forecast Analysis: Solid Tumors (Pipeline)
  • Revenue Forecast Analysis: Hematological Cancer (Launched)
  • Revenue Forecast Analysis: Hematological Cancer (Late-stage Pipeline)

Companies to Action: ADC Market Disruptors

  • Tubulis: Broad Spectrum of Technology Platforms
  • LCB: Conjugation Technology Platforms
  • Synaffix (Lonza): End-to-end ADC Services
  • WuXi Biologics: ADC CRDMO
  • Mersana Therapeutics: Late-stage ADC Pipeline and Platform
  • Iksuda: A Toolbox Approach for ADC Development

Growth Opportunity Universe

  • Growth Opportunity 1: ADC Combination Therapies for Precision Chemotherapeutics
  • Growth Opportunity 2: Strategic Partnerships between CDMOs and Early-stage Platform and ADC Developers
  • Growth Opportunity 3: Novel Linkers and Conjugation Chemistries
  • List of Exhibits
  • Legal Disclaimer